A new study reveals how C210, a curcumin derivative, selectively reactivates Epstein–Barr virus to kill cancer cells without infectious risks, paving the way for safer, targeted cancer therapies.
Francesca has an MSci in Biochemistry from the University of Birmingham.View full profile Francesca has an MSci in Biochemistry from the University of Birmingham. Epstein-Barr Virus (EBV) is very ...
Viral DNA that is usually dismissed when sequencing the human genome could help to uncover useful information about complex ...
Researchers at the Wistar Institute and their collaborators say they have discovered a potential target for gastric cancers associated with Epstein-Barr Virus. The study “Decitabine disrupts EBV ...
Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients No significant financial relationships to disclose. This is an ASCO Meeting ...
PHILADELPHIA—(August 22, 2023)—Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results